Tagraxofusp

{{Short description|Pharmaceutical drug}}

{{Use dmy dates|date=July 2024}}

{{Infobox drug

| image =

| alt =

| caption =

| pronounce = {{IPAc-en|t|ə|g|ˈ|r|æ|k|s|ə|f|ʌ|s|p}}
{{respell|təg|RAKS|ə|fusp}}

| tradename = Elzonris

| Drugs.com = {{Drugs.com|monograph|tagraxofusp-erzs}}

| MedlinePlus = a619022

| DailyMedID = Tagraxofusp

| pregnancy_AU =

| pregnancy_AU_comment =

| pregnancy_category=

| routes_of_administration = Intravenous

| class =

| ATC_prefix = L01

| ATC_suffix = XX67

| legal_AU =

| legal_AU_comment =

| legal_BR =

| legal_BR_comment =

| legal_CA =

| legal_CA_comment =

| legal_DE =

| legal_DE_comment =

| legal_NZ =

| legal_NZ_comment =

| legal_UK =

| legal_UK_comment =

| legal_US = Rx-only

| legal_US_comment =

| legal_EU = Rx-only

| legal_EU_comment = {{cite web | title=Elzonris Product information | website=Union Register of medicinal products | url=https://ec.europa.eu/health/documents/community-register/html/h1504.htm | access-date=3 March 2023}}

| legal_UN =

| legal_UN_comment =

| legal_status =

| bioavailability =

| protein_bound =

| metabolism = Proteases (expected)

| metabolites =

| onset =

| elimination_half-life = 51 minutes

| duration_of_action =

| excretion =

| CAS_number = 2055491-00-2

| CAS_supplemental =

| PubChem =

| IUPHAR_ligand =

| DrugBank = DB14731

| ChemSpiderID =

| UNII = 8ZHS5657EH

| KEGG = D11358

| ChEBI =

| ChEMBL =

| NIAID_ChemDB =

| PDB_ligand =

| synonyms = DT388-IL3, SL-401, tagraxofusp-erzs

| C=2553 | H=4026 | N=692 | O=798 | S=16

}}

Tagraxofusp, sold under the brand name Elzonris, is an anti-cancer medication for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN).{{cite journal | vauthors = Hammond D, Pemmaraju N | title = Tagraxofusp for Blastic Plasmacytoid Dendritic Cell Neoplasm | journal = Hematology/Oncology Clinics of North America | volume = 34 | issue = 3 | pages = 565–574 | date = June 2020 | pmid = 32336420 | doi = 10.1016/j.hoc.2020.01.005 | s2cid = 216261672 }}{{cite journal | vauthors = Lee SS, McCue D, Pemmaraju N | title = Tagraxofusp as treatment for patients with blastic plasmacytoid dendritic cell neoplasm | journal = Expert Review of Anticancer Therapy | volume = 20 | issue = 7 | pages = 543–550 | date = July 2020 | pmid = 32460559 | doi = 10.1080/14737140.2020.1776120 | s2cid = 218974611 | url = }}

Tagraxofusp is a fusion protein consisting of interleukin 3 (IL-3) fused to diphtheria toxin.{{Cite web | url = https://stemline.com/pipeline | title = Elzonris (tagraxofusp, SL-401) | publisher = Stemline Therapeutics}}{{cite web | title=Elzonris- tagraxofusp injection, solution | website=DailyMed | date=9 June 2020 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=80eb1080-fe20-4af0-b2a5-a67999923fa8 | access-date=21 September 2020}} The fusion protein readily kills cultured pDC by binding to their IL-3 receptors to thereby gain entrance to the cells and then blocking these cells' protein synthesis (due to its diphtheria toxin portion inhibiting eukaryotic elongation factor 2).{{medcn|date=September 2020}}

It was approved for use in the United States in 2018,{{Cite press release | url = https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-rare-blood-disease | archive-url = https://web.archive.org/web/20191211193234/https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-rare-blood-disease | url-status = dead | archive-date = 11 December 2019 | title = FDA approves first treatment for rare blood disease | publisher = U.S. Food and Drug Administration (FDA) | date = 21 December 2018}} and in the European Union in January 2021. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.{{cite report | title=New Drug Therapy Approvals 2018 | website=U.S. Food and Drug Administration (FDA) | date=January 2019 | url=https://www.fda.gov/media/120357/download | archive-url=https://web.archive.org/web/20190826114431/https://www.fda.gov/media/120357/download | url-status=dead | archive-date=26 August 2019 | format=PDF | access-date=16 September 2020}}